Managed Healthcare Executive February 1, 2025
Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.

Video content...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
STAT+: How Trump’s tariffs may raise health care costs, from medical devices to prescription drugs
Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries
Drugmakers increase prices on 800 medications: 5 things to know

Share This Article